- Home
- SXTP vs PPCB Comparison
SXTP vs PPCB Comparison
Compare SXTP & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SXTP | PPCB |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | Australia |
| Employees | 3 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 3.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SXTP | PPCB |
|---|---|---|
| Price | $2.05 | $0.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.60 | N/A |
| AVG Volume (30 Days) | 46.6K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $146.28 | N/A |
| Revenue Next Year | $24.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.16 |
| 52 Week High | $8.62 | $10.69 |
Technical Indicators
Market Signals| Indicator | SXTP | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 35.03 | 30.64 |
| Support Level | $1.99 | $0.16 |
| Resistance Level | $2.58 | $0.40 |
| Average True Range (ATR) | 0.25 | 0.02 |
| MACD | -0.21 | 0.01 |
| Stochastic Oscillator | 1.27 | 12.02 |
Price Performance
Historical ComparisonAbout SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.